Published in Am J Cardiol on April 21, 2006
Acute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc (2009) 0.93
Influence of the Timing of Percutaneous Coronary Intervention on Clinical Outcomes in Non-ST-Elevation Myocardial Infarction. Korean Circ J (2013) 0.79
No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction. Chonnam Med J (2016) 0.75
A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. Eur Heart J Acute Cardiovasc Care (2012) 0.75
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg (2005) 4.95
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation (2004) 4.13
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care (2009) 2.96
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Same-day discharge after percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol (2013) 2.80
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med (2006) 2.38
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2007) 2.36
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation (2012) 2.17
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv (2005) 2.00
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol (2006) 2.00
Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol (2006) 1.94
Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J (2008) 1.92
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res (2010) 1.84
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv (2009) 1.77
Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol (2010) 1.76
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.74
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med (2007) 1.72
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol (2005) 1.72
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2012) 1.66
Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv (2012) 1.65
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2012) 1.65
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis (2008) 1.63
Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol (2011) 1.62
Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation (2002) 1.60
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.59
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58
Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 1.55
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J (2005) 1.54
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J (2010) 1.52
Limitations of the MEDLINE database in constructing meta-analyses. Ann Intern Med (2010) 1.48
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting. J Am Coll Cardiol (2013) 1.48
Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension (2012) 1.46
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials. J Hypertens (2014) 1.45
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study. Catheter Cardiovasc Interv (2012) 1.44
An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol (2008) 1.44
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? Am Heart J (2006) 1.44
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. JACC Cardiovasc Interv (2010) 1.43
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol (2003) 1.42
Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Catheter Cardiovasc Interv (2010) 1.41
Predictors and Outcomes of Side-Branch Occlusion in Coronary Chronic Total Occlusion Interventions. J Invasive Cardiol (2016) 1.41
Drug-eluting stents: the beginning of the end of restenosis? Cleve Clin J Med (2004) 1.41
Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes (2014) 1.41
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol (2004) 1.40
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia. JACC Cardiovasc Interv (2009) 1.40
Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry. JACC Cardiovasc Interv (2011) 1.39
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol (2005) 1.39
Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2008) 1.37
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics (2011) 1.37
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv (2009) 1.35
Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med (2006) 1.33
Aspiration thrombectomy in patients undergoing primary angioplasty: totality of data to 2013. Catheter Cardiovasc Interv (2014) 1.33
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol (2006) 1.30
GOSR2 Lys67Arg is associated with hypertension in whites. Am J Hypertens (2008) 1.20
Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol (2006) 1.18
Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol (2011) 1.17
Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coll Cardiol (2006) 1.17
Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction. PLoS One (2008) 1.17
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17
Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol (2004) 1.16
Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.15
Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol (2004) 1.15
An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Interv Cardiol (2010) 1.14
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol (2006) 1.14
Development of coronary aneurysm after drug-eluting stent implantation. Ann Intern Med (2007) 1.14
Drug-eluting stent fracture and acute coronary syndrome. Cardiovasc Revasc Med (2009) 1.14